Boehringer Ingelheim’s drug, survodutide, has shown promising results in a mid-stage clinical trial for treating metabolic dysfunction-associated steatohepatitis (MASH) in patients with fatty liver disease. The drug demonstrated significant improvements in liver fibrosis without any safety issues. The drug, developed in collaboration with Zealand Pharma, targets gut hormone receptors to decrease appetite and increase energy expenditure. Boehringer Ingelheim believes survodutide could be a best-in-class treatment for MASH. However, financial analysts express caution, citing limitations in the data and the need for more information on patient enrollment, adherence to treatment, and safety profiles. The FDA is expected to make a decision on another potential MASH treatment, resmetirom, in March.
Source link
Boehringer Ingelheim’s Liver Drug Data Position It for MASH Clash With Eli Lilly
